Renal failure following liver transplantation;Insuffisance rénale après transplantation hépatique

Presse Medicale

Volumn 38, Issue 9, 2009, Pages 1314-1318

  Calmus, Yvon ^a   Pageaux, Georges ^b  

^a Institut Cochin   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; HETASTARCH; LIPID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AGE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ETHNICITY; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MEDICAL RESEARCH; NEPHROSCLEROSIS; RENAL REPLACEMENT THERAPY; SEX DIFFERENCE; SHORT SURVEY;

CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; RISK FACTORS;

EID: 69549103066     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.05.006     Document Type: Short Survey

References (20)

1. European Liver Transplant Registry. http://www.eltr.org/publi/results.php3.
2. Fisher N.C., Nightingale P.G., Gunson B.K., Lipkin G.W., and Neuberger J.M. Chronic renal failure following liver transplantation. Transplantation 66 (1998) 59-66
3. Gonwa T.A., Mai M.L., Melton L.B., Hays S.R., Goldstein R.M., Levy M.F., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using clacineurin-based immunotherapy: risk of development and treatment. Transplantation 72 (2001) 1934-1939
4. Cohen A.J., Stegall M.D., Rosen C.B., Wiesner R.H., Leung N., Kremers W.K., et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 8 (2002) 916-921
5. Wilkinson A., and Pham P.T. Kidney dysfunction in the recipients of liver transplants. Liver Transplant 11 (2005) S47-51
6. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney disease: improving global outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
7. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of nonrenal organ. N Engl J Med 349 (2003) 931-940
8. Gonwa T.A., Jennings L., Mai M.L., Stark P.C., Levey A.S., and Klintmalm G.B. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transplant 10 (2004) 301-309
9. Morard I., Mentha G., Spahr L., Majno P., Hadengue A., Huber O., et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 20 (2005) 96-101
10. Pillebout E., Nochy D., Hill G., Cont I.F., Antoine C., Calmus Y., et al. Renal histopathological lesions after orthotopic liver. Am J Transplant 5 (2005) 1120-1129
11. Thuluvath P.J. When is diabetes mellitus a relative or absolute contraindication to liver transplantation?. Liver Transpl 11 (2005) S25-S29
12. Bahirwani R., Campbell M.S., Siropaides T., Markmann J., Olthoff K., Shaked A., et al. Transplantation: impact of pretransplant renal insufficiency. Liver Transpl 14 (2008) 665-671
13. Pageaux G.P., Calmus Y., Boulot O., Ducerf C., Vanlemmens C., Boudjema K., et al. French CHI- F-O1 Study Group. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Iranspl 10 (2004) 1454-1460
14. Sher L., Marotta P., Teperman L., Sebastian A., Moonka D., Koneru B., et al. Spare-The-Nephron (STN) trial in liver transplant recipients : Interim efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after CNI withdrawal. Am J Transplant 8 (2008) 179 abstract
15. Wadei H.M., Mai M., Ahsan N., Rosser B.G., and Gonwa T.A. High risk of proteinuria and lack of improvement of kidney function following sirolimus conversion in liver transplant recipients. Am J Transplant 8 (2008) 543 abstract
16. Mayer A.D., and Neuberger J.M. Benefit of mycophenolate mofetil, delayed and reduced tacrolimus and daclizumab in de novo liver transplantation - supportive evidence from the 1-year per protocol population and additional analyses. Am J Transplant 8 (2008) 307 abstract
17. Mells G., and Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 83 (2007) 1141-1150
18. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
19. Julius S., Majahalme S., and Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 14 (2001) 310S-316S
20. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 7 (2001) S13-21